Arbutus Biopharma (ABUS) News Today → The biggest energy story ever? (From Porter & Company) (Ad) Free ABUS Stock Alerts $2.69 -0.04 (-1.47%) (As of 05/1/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineArbutus Biopharma earnings: here's what to expectmarkets.businessinsider.com - May 1 at 10:35 PMArbutus Biopharma Q1 2024 Earnings Previewmsn.com - May 1 at 12:34 PMArbutus Biopharma Corpmoney.usnews.com - April 30 at 9:32 PMArbutus Biopharma (ABUS) to Release Earnings on Thursdayamericanbankingnews.com - April 25 at 3:58 AMArbutus Biopharma Sets Date for Q1 2024 Financial Resultsmsn.com - April 21 at 10:37 AMArbutus to Report First Quarter 2024 Financial Results and Provide Corporate Updateglobenewswire.com - April 18 at 7:30 AMArbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remainsseekingalpha.com - April 10 at 7:31 AMArbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judgemsn.com - April 4 at 4:37 PMArbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volumemarketbeat.com - April 4 at 2:02 PMArbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against Modernamarkets.businessinsider.com - April 4 at 10:42 AMArbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP Securitiesmarketbeat.com - April 4 at 9:15 AMArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Modernaglobenewswire.com - April 4 at 8:30 AMArbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25marketbeat.com - April 3 at 4:30 PMArbutus Biopharma jumps after claim construction order in patent fight with Modernaseekingalpha.com - April 3 at 1:17 PMmarketbeat.com - April 3 at 12:22 PMIs Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - April 1 at 3:37 PMABUS Jan 2025 7.000 callfinance.yahoo.com - March 19 at 10:43 AMHudson Bay Capital Management LP Purchases 1,302,978 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)marketbeat.com - March 14 at 7:25 AMArbutus Biopharma to Participate in Prominent Investor Conferencesmsn.com - March 12 at 12:37 AMArbutus to Participate in Two Upcoming Investor Conferencesglobenewswire.com - March 8 at 7:30 AMArbutus Biopharma Target of Unusually Large Options Trading (NASDAQ:ABUS)marketbeat.com - March 6 at 1:53 PMFY2024 EPS Estimates for Arbutus Biopharma Co. Raised by Chardan Capital (NASDAQ:ABUS)marketbeat.com - March 6 at 8:13 AMArbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Reportfinance.yahoo.com - March 3 at 12:08 PMAnalysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecastsfinance.yahoo.com - March 2 at 10:36 AMArbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Meets Estimatesmarketbeat.com - March 1 at 4:13 PMArbutus Biopharma (NASDAQ:ABUS) Given New $5.00 Price Target at HC Wainwrightmarketbeat.com - March 1 at 8:33 AMArbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 8:33 AMArbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from Chardan Capitalmarketbeat.com - March 1 at 8:28 AMBuy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospectsmarkets.businessinsider.com - March 1 at 1:26 AMQ4 2023 Arbutus Biopharma Corp Earnings Callfinance.yahoo.com - March 1 at 1:26 AMArbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:24 AMArbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trialsfinance.yahoo.com - February 29 at 10:24 AMArbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 7:30 AMABUS Jun 2024 3.000 putfinance.yahoo.com - February 28 at 12:54 AMABUS Apr 2024 6.000 callfinance.yahoo.com - February 27 at 8:05 AMABUS Apr 2024 3.000 callfinance.yahoo.com - February 23 at 2:49 AMABUS Sep 2024 3.000 callfinance.yahoo.com - February 23 at 2:49 AMArbutus Biopharma Set to Announce 2023 Year-End Financial Results, Offering Insight into Hepatitis B Cure Progressmsn.com - February 17 at 7:29 AMArbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Updatefinance.yahoo.com - February 15 at 9:04 AMArbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Updateglobenewswire.com - February 15 at 7:30 AMArbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200 Day Moving Average of $2.10marketbeat.com - February 15 at 3:11 AMArbutus Biopharma gains after Markman hearing on Thursday in Moderna disputemsn.com - February 9 at 4:20 PMArbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above Two Hundred Day Moving Average of $2.08marketbeat.com - February 7 at 7:23 AMThe past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitablefinance.yahoo.com - February 2 at 1:00 PMArbutus Biopharma Corporation (ABUS)ca.finance.yahoo.com - January 31 at 11:27 PMArbutus Biopharma Corporation (ABUS)ca.finance.yahoo.com - January 31 at 11:27 PMChardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)markets.businessinsider.com - January 30 at 7:18 AMArbutus Biopharma (NASDAQ:ABUS) Shares Pass Above 200 Day Moving Average of $2.07marketbeat.com - January 30 at 3:03 AMOptimistic Outlook for Arbutus Biopharma Amid Anticipated Positive Data and Strategic Pipeline Developmentsmarkets.businessinsider.com - January 11 at 1:13 PMArbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospectsmarkets.businessinsider.com - January 10 at 9:33 AM Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here ABUS Media Mentions By Week ABUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼-0.200.34▲Average Medical News Sentiment ABUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼42▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OCS News CMPS News ANAB News KALV News APLT News STOK News FULC News ANL News AVBP News ATXS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.